5 COVID-19 VACCINES UNDER CLINICAL TRIALS IN INDIA

5 MORE COVID-19 VACCINES UNDER TRIALS IN INDIA 2021

In order to respond quickly and effectively to the COVID-19 pandemic, a broad range of candidate COVID-19 vaccines are being investigated globally using various technologies and platforms. These include viral-vectored, protein subunit, nucleic acid (DNA, RNA), live attenuated and inactivated vaccines. Previously two candidates of the vaccine have been approved for emergency use i.e. Covishield & Covaxin. Some of these candidates have entered under clinical trials.

  1. ZyCov-D
  2. Biological E’s novel Covid-19 vaccine
  3. BBV154 – Intranasal vaccine
  4. COVOVAX
  5. mRNA based vaccine (HGCO19)

ZyCoV-D

Zydus Cadila, ZyCoV-D

Zydus Cadila, focused on discovering and developing NCEs, Novel Biologicals, Biosimilars and Vaccines, announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D. Safety in Phase I clinical trial of ZyCoV-D in healthy subjects established as endorsed by the independent Data Safety Monitoring Board (DSMB). Zydus commenced Phase II trial.

  • DCGI approval for Phase I & Phase II Human Clinical Trials RECEIVED
  •  Phase I Human Clinical Trial COMPLETED
  •  Phase II Human Clinical Trial COMPLETED
  •  Phase III Human Clinical Trial ONGOING
  •  DCGI approval for Phase III Human Clinical

Biological E’s novel Covid-19 vaccine

Biological E’s novel Covid-19 vaccine

Biological E. Limited is conducting a prospective open label randomised Phase-I seamlessly followed by Phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E’s novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule(0, 28D) to healthy volunteers.

  • DCGI approval for Phase I & Phase II Human Clinical Trials RECEIVED
  •  Phase I/II Human Clinical Trial ONGOING

BBV154 – Intranasal vaccine

BBV154 – Intranasal vaccine

Bharat Biotech is conducting Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenoviral vector COVID-19 vaccine (BBV154) in Healthy Volunteers. BBV154 is an intranasal vaccine that stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.  Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19.

  •  DCGI approval for Phase I Human Clinical Trials RECEIVED
  •  Phase I Human Clinical Trial ONGOING.

COVOVAX

COVOVAX

Indian Council of Medical Research and Serum Institute of India jointly performing a phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults.

  •  DCGI approval for Phase 2/3 Human Clinical Trial RECEIVED
  •  Phase 2/3 Human Clinical Trial ONGOING

mRNA based vaccine (HGCO19)

HGCO19

Randomized, Phase I/II, Placebo-controlled, Dose-Ranging, study to evaluate the Safety, Tolerability and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy adult subjects. The trial is being conducted by Gennova Biopharmaceuticals Limited.

  • DCGI approval for Phase I/II Human Clinical Trial RECEIVED
  •  Phase I/II Human Clinical Trial ONGOING.

Bibliography: Indian Council of Medical Research (ICMR) & WHO.

close

Sign up to receive latest updates in your inbox.

Leave a Comment

Your email address will not be published.

Open chat
1
Need Help?
Welcome to The Pharmapedia
Hello,
How can we help you?
%d bloggers like this: